Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

0.7825 +0.0146 (+1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 252,543
Open 0.7700
Bid (Size) 0.7825 (1)
Ask (Size) 0.7833 (1)
Prev. Close 0.7679
Today's Range 0.7500 - 0.7849
52wk Range 0.6801 - 2.650
Shares Outstanding 1,357,031,946
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces... 
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
-53.14%
-53.14%
1 Month
-4.14%
-4.14%
3 Month
-17.63%
-17.63%
6 Month
-28.86%
-28.86%
1 Year
-41.17%
-41.17%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Analyst Expectations for Adaptimmune Therapeutics's Future
Via Benzinga
Adaptimmune Reports Second Quarter Financial Results and Business Update
Via Newsfile
Exposures Product Safety
Recap: Adaptimmune Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Adaptimmune Therapeutics
Via Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Via Benzinga
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Via Newsfile
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Via Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Via Newsfile
Earnings Scheduled For May 12, 2023
Via Benzinga
Adaptimmune Reports First Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Via Newsfile
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Via The Motley Fool
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Via Newsfile
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via GlobeNewswire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
Via Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.